49P Analysis of HER2-low carcinomas and PAM50 signature in an early-stage breast cancer cohort
Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Eva Ciruelos, M. Rey Cardenas(Hospital Universitario 12 De Octubre), L. Lema Roso(Hospital Universitario 12 De Octubre), Manuel A. Bianchi(Hospital Universitario 12 De Octubre), Luís Manso(Research Institute Hospital 12 de Octubre), Santiago Terán(Hospital Universitario 12 De Octubre), Pablo Tolosa(Research Institute Hospital 12 de Octubre), A. Madariaga Urrutia(Hospital Universitario 12 De Octubre), Yolanda Ruano(Hospital Virgen de la Salud)
Cited by 1
Related Papers
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
|Annals of Oncology|2021|799
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
|Critical Reviews in Oncology/Hematology|2018|268
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
|The Lancet|2023|225
DNA-Repair Gene Polymorphisms Predict Favorable Clinical Outcome Among Patients With Advanced Squamous Cell Carcinoma of the Head and Neck Treated With Cisplatin-Based Induction Chemotherapy
|Journal of Clinical Oncology|2006|149
Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and <i>BRAF</i> <i>V600E</i> mutation
|The Journal of Experimental Medicine|2019|136